The Chemours Company Reports Second Quarter Results
Chemours (NYSE: CC) reported Q2 2026 results: net sales about $1.6B, roughly flat year over year. Net loss attributable to Chemours was $274M ($1.81 per diluted share) versus $380M ($2.53) a year earlier. Adjusted net income was $64M ($0.42) and adjusted EBITDA $247M. Free cash flow rose 128% and net leverage fell to 4.4x. Chemours cited TiO2 pricing actions and APM Performance Solutions growth.
How this was made
The 30-second read
Why it matters
Traders can update models for cash generation, leverage trajectory, and segment profitability drivers (pricing versus volume, and outage/closure cost impacts).
Market read
The release combines a cash/leverage positive with profitability headwinds in APM and lower adjusted EBITDA versus the prior year, plus a fresh TiO2 price increase effective June 1.
What to watch
Legacy litigation reserve movements (EPA and WVDEP settlement-related reserves) can swing reported losses and may affect investor focus on underlying operating performance versus one-time legal/tax items.
Background
Chemours is reporting Q2 2026 performance across TSS, TT, and APM, with emphasis on pricing actions (notably TiO2) and balance-sheet progress.
Ticker impact
Chemours reported Q2 2026 results, including net loss of $274M, adjusted EBITDA of $247M, and free cash flow up 128% YoY.
Near-term bias depends on how the market weighs improved free cash flow and leverage progress versus weaker adjusted EBITDA and APM margin compression.
The article provides multiple decision-relevant datapoints (cash flow conversion, net leverage down to 4.4x, TiO2 pricing actions, and segment EBITDA/margin changes) but does not include guidance or consensus comparisons to calibrate magnitude versus expectations.
Market effects
TiO2 pricing actions and volume softness in TiO2 end markets may influence read-across expectations for other pigment and specialty chemical pricing power.
North America stationary AC aftermarket demand dynamics (AIM Act channel fill comparison) highlight regional demand normalization effects.
Global TiO2 pricing strength versus volume declines (with Asia ex-China and Latin America exceptions) signals uneven end-market recovery.
Counterpoint
Cash flow improvement could be partly timing-driven, while adjusted EBITDA and APM margins are still deteriorating due to outage and line-closure impacts.
Key entities
- companyThe Chemours Company
Reported Q2 2026 net loss, adjusted EBITDA, free cash flow improvement, and segment results across TSS, TT, and APM.
- executiveDenise Dignam
CEO who attributed performance to pricing actions, APM momentum in data center and semiconductor end markets, and progress on balance sheet and legacy litigation.
